Eli Lilly beats earnings, lifts outlook on booming Zepbound and Mounjaro sales

Eli Lilly reported stronger-than-expected fourth-quarter earnings and issued robust guidance for the coming year, as soaring demand for its GLP-1 drugs reaffirmed its dominance in the global weight-lo... ...